Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Shares, without par value
-
Shares outstanding
-
193M
-
Number of holders
-
70
-
Total 13F shares, excl. options
-
21.9M
-
Shares change
-
-1.82M
-
Total reported value, excl. options
-
$77.7M
-
Value change
-
-$4.92M
-
Put/Call ratio
-
1.41
-
Number of buys
-
44
-
Number of sells
-
-21
-
Price
-
$3.55
Significant Holders of Arbutus Biopharma Corp - Common Shares, without par value (ABUS) as of Q4 2020
96 filings reported holding ABUS - Arbutus Biopharma Corp - Common Shares, without par value as of Q4 2020.
Arbutus Biopharma Corp - Common Shares, without par value (ABUS) has 70 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 21.9M shares
of 193M outstanding shares and own 11.32% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (5.98M shares), VANGUARD GROUP INC (2.75M shares), Think Investments LP (2M shares), BlackRock Inc. (1.82M shares), MORGAN STANLEY (1.42M shares), ADVISOR GROUP HOLDINGS, INC. (1.37M shares), Charles Winkler (725K shares), AMERIPRISE FINANCIAL INC (637K shares), PRIMECAP MANAGEMENT CO/CA/ (500K shares), and COWEN AND COMPANY, LLC (465K shares).
This table shows the top 70 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.